lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Zverev's next breakthrough came during the grass court season at the Halle Open, where he upset world No. 3 Roger Federer in the semifinals, ending Federer's streak of ten consecutive appearances in the final while competing at the tournament. He was also the first teenager to defeat Federer since Murray nearly a decade earlier. Nonetheless, he finished runner-up at the event to veteran compatriot Florian Mayer. After this final, he entered the top 30 for the first time and stayed ranked in the 20s for the rest of the season. Despite being seeded at a major tournament for the first time, Zverev could then only match his best major singles result at Wimbledon, again falling to Berdych. During the US Open Series, he reached the semifinals of the Washington Open, but lost his opening round matches at both Masters events. He was then upset in the second round of the US Open by Dan Evans. After the US Open, Zverev returned to Europe and won his first career ATP title at the St. Petersburg Open. He recorded his first win over No. 9 Berdych in the semifinals, and No. 3 Stan Wawrinka in the final, coming back from 0–3 down in the third set. At his next event, he then defeated No. 10 Thiem in the first round of the 2016 China Open for the first time in four tries this year. In doing so, Zverev became the first teenager to record three consecutive victories against top ten opponents since Boris Becker in 1986. Zverev's third round appearance at the Shanghai Masters then helped him rise to No.
== Prognosis == The length of the trinucleotide repeat accounts for 60% of the variation of the age of symptoms onset and their rate of progress. A longer repeat results in an earlier age of onset and a faster progression of symptoms. Individuals with more than sixty repeats often develop the disease before age 20, while those with fewer than 40 repeats may remain asymptomatic. The remaining variation is due to environmental factors and other genes that influence the mechanism of the disease. Life expectancy in HD is generally around 15 to 20 years following the onset of visible symptoms. Juvenile Huntington's disease has a life expectancy rate of 10 years after onset of visible symptoms. People with Huntington's disease usually have a reduced lifespan of around 58–63 years (mean), although it varies considerably, and different studies give slightly different ages. Most life-threatening complications result from muscle coordination, and to a lesser extent, behavioral changes induced by declining cognitive function. The largest risk is pneumonia, which causes death in one third of those with HD. As the ability to synchronize movements deteriorates, difficulty clearing the lungs, and an increased risk of aspirating food or drink both increase the risk of contracting pneumonia. The second-greatest risk is heart disease, which causes almost a quarter of fatalities of those with HD. Suicide is the third greatest cause of fatalities, with 7.3% of those with HD taking their own lives and up to 27% attempting to do so.
Carrey reunited with Joel Schumacher, director of Batman Forever, for The Number 23 (2007), a psychological thriller co-starring Virginia Madsen and Danny Huston. In the film, Carrey plays a man who becomes obsessed with the number 23, after finding a book about a man with the same obsession. The film was panned by critics. The following year Carrey provided his voice for Dr. Seuss' Horton Hears a Who! (2008). Carrey voiced Horton the Elephant for the CGI-animated feature, which was a box office success, grossing over $290 million worldwide. Carrey returned to live-action comedy, starring opposite Zooey Deschanel and Bradley Cooper in Yes Man (also 2008). Carrey played a man who signs up for a self-help program that teaches him to say yes to everything. Despite reviews being mixed, Rene Rodriquez of The Miami Herald stated, "Yes Man is fine as far as Jim Carrey comedies go, but it's even better as a love story that just happens to make you laugh." The film earned $225 million at the box office worldwide.
Nearly 40,000 workers and harvesters in the provinces of Newfoundland and Labrador applied for the federal relief program TAGS (the Atlantic Groundfish Strategy). Abandoned and rusting fishing boats still litter the coasts of Newfoundland and the Canadian northwest to this day. The fishery minister, John Crosbie, after delivering a speech on the day before the declaration of the moratorium, or July 1, 1992, was publicly heckled and verbally harassed by disgruntled locals at a fishing village. The moratorium, initially lasting for only two years, was indefinitely extended after it became evident that cod populations had not recovered at all but, instead, had continued to spiral downward in both size and numbers, due to the damage caused by decades of destructive fishing practices, and the fact that the moratorium had permitted exceptions for food fisheries for "personal consumption" purposes to this very day. Some 12,000 tons of Northwest cod are still being caught every year along the Newfoundland coast by local fishermen. The collapse of the four-million ton biomass, which had persevered through several previous marine extinctions over tens of millions of years, in a timespan of no more than 20 years, is oft-cited by researchers as one of the most visible examples of the phenomenon of the "Tragedy of the Commons." Factors which had been implicated as contributing to the collapse include: overfishing; government mismanagement; the disregard of scientific uncertainty; warming habitat waters; declining reproduction; and plain human ignorance.
== Further reading == Perkins, D. H. (1984-12-01). "Proton Decay Experiments". Annual Review of Nuclear and Particle Science. 34 (1): 1–50. Bibcode:1984ARNPS..34....1P. doi:10.1146/annurev.ns.34.120184.000245. ISSN 0163-8998. Luciano Maiani (8 February 2006). The problem of proton decay (PDF). Third NO-VE International Workshop on Neutrino Oscillations in Venice. Venice. Nath, Pran; Fileviez Pérez, Pavel (April 2007). "Proton stability in grand unified theories, in strings and in branes". Physics Reports. 441 (5–6): 191–317. arXiv:hep-ph/0601023. Bibcode:2007PhR...441..191N. doi:10.1016/j.physrep.2007.02.010. S2CID 119542637. Dev, P. S. B.; et al. (2022-09-26), "Searches for Baryon Number Violation in Neutrino Experiments: A White Paper", Journal of Physics G: Nuclear Physics, 51 (3): 033001, arXiv:2203.08771, Bibcode:2024JPhG...51c3001D, doi:10.1088/1361-6471/ad1658
Sources: en.wikipedia.org
Estradiol has been studied and used by intranasal administration. It was available as a cyclodextrin-containing nasal spray under the brand name Aerodiol in some countries, although this specific product was discontinued in 2007. The product was administered once per day as one 150-μg spray in each nostril (300 μg/day total). Intranasal estradiol has pharmacokinetics similar to those of sublingual and intravenous administration of estradiol, including a sharp peak and then rapid decline in estradiol levels. Despite the relatively short duration of intranasal estradiol, it has similar effectiveness to other, longer-lasting routes of administration in terms of relief of menopausal symptoms like hot flashes.
==== Methanol ==== The methanol produced by aspartame metabolism is unlikely to be a safety concern for several reasons. The amount of methanol produced from aspartame-sweetened foods and beverages is likely to be less than that from food sources already in diets. With regard to formaldehyde, it is rapidly converted in the body, and the amounts of formaldehyde from the metabolism of aspartame are trivial when compared to the amounts produced routinely by the human body and from other foods and drugs. At the highest expected human doses of consumption of aspartame, there are no increased blood levels of methanol or formic acid, and ingesting aspartame at the 90th percentile of intake would produce 25 times less methanol than what would be considered toxic.
== Reactivity == Like most alkanes, hexanes typically exhibit low reactivity and are suitable solvents for reactive compounds. Commercial samples of n-hexane however often contains methylcyclopentane, which features tertiary C-H bonds, which are incompatible with some radical reactions.
=== Anhydrous structure === Anhydrous Dy(ClO4)3 crystallizes in the hexagonal crystal system, space group P63/m (No. 176). It is isostructural with the anhydrous perchlorates of La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Ho and Er, and belongs to a structure family related to the UCl3 type. In this structure the Dy3+ centres are nine-coordinate. The coordination environment is formed by oxygen atoms belonging to perchlorate groups, which act as multidentate ligands and generate a three-dimensional channel-containing framework. Across the lanthanide series, the lattice parameters decrease systematically because of the lanthanide contraction.
Sources: en.wikipedia.org
== History == Phage display was first described by George P. Smith in 1985, when he demonstrated the display of peptides on filamentous phage (long, thin viruses that infect bacteria) by fusing the virus's capsid protein to one peptide out of a collection of peptide sequences. This displayed the different peptides on the outer surfaces of the collection of viral clones, where the screening step of the process isolated the peptides with the highest binding affinity. In 1988, Stephen Parmley and George Smith described biopanning for affinity selection and demonstrated that recursive rounds of selection could enrich for clones present at 1 in a billion or less. In 1990, Jamie Scott and George Smith described creation of large random peptide libraries displayed on filamentous phage. Phage display technology was further developed and improved by groups at the Laboratory of Molecular Biology with Greg Winter and John McCafferty, The Scripps Research Institute with Richard Lerner and Carlos Barbas and the German Cancer Research Center with Frank Breitling and Stefan Dübel for display of proteins such as antibodies for therapeutic protein engineering. Smith and Winter were awarded a half share of the 2018 Nobel Prize in chemistry for their contribution to developing phage display. A patent by George Pieczenik claiming priority from 1985 also describes the generation of peptide libraries.
The American National Library of Medicine also stated in an article in 2018 that the consequences of FGM/C have both physiological and psychological complications, including short- and long-term complications. The method in which the procedure is performed may determine the extent of the short-term complications. If the process was completed using unsterile equipment, no antiseptics, and no antibiotics, the victim may have increased risk of complications. Primary infections include staphylococcus infections, urinary tract infections, excessive and uncontrollable pain, and hemorrhaging. Infections such as human immunodeficiency virus (HIV), Chlamydia trachomatis, Clostridium tetani, and herpes simplex virus (HSV) 2 are significantly more common among women who underwent Type 3 mutilation compared with other categories.
=== Liver transplantation === Usually, MSUD patients are monitored by a dietitian. Liver transplantation is a treatment option that can completely and permanently normalize metabolic function, enabling discontinuation of nutritional supplements and strict monitoring of biochemistry and caloric intake, relaxation of MSUD-related lifestyle precautions, and an unrestricted diet. Liver transplantation may increase the BKD function by 10%, which is understood to be enough to prevent buildup of BCAA's that may lead to metabolic consequences. This procedure is most successful when performed at a young age, and weaning from immunosuppressants may even be possible in the long run. However, the surgery is a major undertaking requiring extensive hospitalization and rigorous adherence to a tapering regimen of medications. Following transplant, the risk of periodic rejection will always exist, as will the need for some degree of lifelong monitoring in this respect. Despite normalizing clinical presentation, liver transplantation is not considered a cure for MSUD. The patient will still carry two copies of the mutated BKAD gene in each of their cells, which will consequently still be unable to produce the missing enzyme. They will also still pass one mutated copy of the gene on to each of their biological children. As a major surgery, the transplant procedure itself also carries standard risks, although the odds of its success are greatly elevated when the only indication for it is an inborn error of metabolism.
=== In stimulation === It is possible for some men to achieve orgasm solely through stimulation of the prostate gland, such as via prostate massage or anal intercourse. This has led to the area of the rectal wall adjacent to the prostate to be popularly referred to as the "male G-spot".
=== Commercial development === By the late 1960s, increasing volumes of whey had become an economic and environmental problem for the New Zealand dairy industry, creating an incentive to develop higher-value uses for its whey protein. In September 1969, Dr. Alex Malaspina, vice-president responsible for new product development and quality control at The Coca-Cola Export Corporation, approached the New Zealand Dairy Board in search of a reliable supply of soluble whey protein for acidic, carbonated beverages, with potential demand estimated at as much as 10,000 tons annually. At the time, the New Zealand industry did not know how to manufacture such a product because its existing heat-precipitated whey protein was insoluble and unsuitable for beverages. The Dairy Board and the New Zealand Dairy Research Institute (NZDRI) investigated several separation technologies, and Malaspina, Dr. R. Fenton-May from Coca-Cola, and NZDRI engineer Dave Woodhams examined ultrafiltration, reverse osmosis, and other processes in the United States. Woodhams recommended ultrafiltration, and in September 1970 NZDRI produced a whey protein concentrate containing 65% protein and meeting Coca-Cola's requirements for beverage solubility and clarity. Malaspina subsequently worked with Brazilian food scientist Roberto H. Moretti on a process for producing whey protein suitable for acidic beverages. Their U.S.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.